Woes mount for Marinus with investor lawsuit, trial failure

The failure of Marinus Pharmaceuticals’ trial for ganaxolone as a treatment for persistent seizures has left the Philadelphia company facing the daunting prospect of conducting a new study to keep its hopes alive in the indication.